Bayer Remains Optimistic About Long-Term Prospects Despite Legal Challenges

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Nov 12 2025

0mins

Source: Benzinga

Earnings Report: Bayer AG reported adjusted earnings of 17 cents per ADS, a significant increase from 7 cents a year ago, with sales reaching $11.29 billion, surpassing expectations.
Sales Performance: The agricultural division saw a 1.3% increase in sales, driven by a 22.4% rise in Corn Seed & Traits, while the Pharmaceuticals division also experienced growth, particularly in prostate cancer and chronic kidney disease treatments.
Consumer Health Challenges: Sales in the Consumer Health segment rose by 2%, but faced challenges in key markets, particularly in North America and Asia-Pacific, with notable declines in Allergy & Cold products.
Litigation and Guidance Update: Bayer anticipates a larger adjusted EBITDA loss for 2025 due to increased litigation costs related to glyphosate cases, while expressing confidence in managing litigation risks by the end of 2026.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.